Uveitis Drug Market: Is "Brepocitinib" the Oral Breakthrough for 2026? A defining 2026 trend in ocular immunology is the transition toward oral TYK2/JAK1 inhibitors as a systemic alternative to traditional steroids. In 2026, the clinical community is closely watching the rollout of brepocitinib, which received Fast Track Designation and has shown promising Phase II results in reducing inflammation for "non-anterior" uveitis. Unlike broad-spectrum...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china